Science & Policy — New Mexico Kratom Advocates
The Distinction That Every Lawmaker Must Understand Before Voting
Natural kratom and synthetic 7-hydroxymitragynine are not the same substance. Treating them as identical in legislation is not a conservative position — it is an uninformed one.
The Core Issue
Two Very Different Things Being Regulated as One
The confusion at the center of most kratom legislation is pharmacological. Policymakers are conflating a traditional botanical leaf with laboratory-engineered synthetic compounds. The consequences of that error fall on ordinary New Mexicans.
Mitragyna speciosa
Used in Southeast Asia for centuries. The dominant alkaloid, mitragynine, acts as a partial agonist — engaging opioid receptors without the respiratory depression that makes opioids deadly.
- 7-OH present at less than 1% of alkaloid content
- Used by millions for pain, energy, and withdrawal support
- No documented fatal dose in plant form
- Centuries of traditional use without mass harm
Laboratory Concentrates
Chemically concentrated or fully synthetic 7-hydroxymitragynine. Found in gas station shots, vapes, and gummies. These are the products driving nearly every safety concern in regulatory reports.
- 5 to 13 times more potent than morphine
- Not present in natural kratom at harmful levels
- Marketed to youth with flavors and bright packaging
- The actual target of legitimate regulatory concern
Banning natural kratom to address synthetic 7-OH is the policy equivalent of prohibiting wine to stop fentanyl poisoning. The substances share a name in public discourse. They do not share a risk profile.
Peer-Reviewed Science
What Two Decades of Research Actually Shows
Dr. Christopher McCurdy, Professor of Medicinal Chemistry at the University of Florida, has studied kratom’s pharmacology longer than almost any researcher in the country. His work draws a clear biochemical line between natural leaf alkaloids and synthetic derivatives — and consistently concludes that the policy response should match the pharmacological reality.
The position of researchers in this field is not that kratom has no risks. It is that the risks of synthetic concentrates are being attributed to natural kratom — and that prohibition of the natural plant removes a tool that thousands of New Mexicans use to manage pain, reduce opioid dependence, and maintain daily function.
Dr. Christopher McCurdy, University of Florida — Kratom Pharmacology Research Overview
What Sound Kratom Policy Actually Looks Like
The Kratom Consumer Protection Act — model legislation now adopted by more than 15 states — provides a framework that directly addresses legitimate concerns without eliminating access to a botanical that millions of Americans depend on. The KCPA does not protect the gas station shot market. It explicitly targets it.
- 18Age restrictions (18+ or 21+) on all kratom sales — closing the youth access gap that concerns regulators
- %Mandatory caps on 7-hydroxymitragynine concentration — the provision that directly eliminates synthetic concentrates from the legal market
- ✓Mandatory labeling of alkaloid content — giving consumers and physicians the information needed to make informed decisions
- ⚙Good Manufacturing Practice standards — requiring independent third-party audits of all kratom vendors
- ✗Prohibition of adulterated, contaminated, or mislabeled products — the actual source of documented consumer harm
A ban on natural kratom does not solve the 7-OH problem. It simply removes the regulated alternative and leaves the synthetic market untouched — while eliminating access for the hundreds of thousands of New Mexicans who use the natural plant safely.
A Direct Address to New Mexico Legislators
Four Questions Worth Asking Before You Vote
These are not rhetorical. We are prepared to provide sourced answers, connect you with researchers, and brief your office on any of these points directly.
If this ban passes, which specific products will be removed from New Mexico shelves — and which ones will remain legally available?
What happens to the New Mexicans currently using natural kratom to manage opioid withdrawal — and what alternative are we offering them?
Has any state that banned natural kratom demonstrated a reduction in synthetic 7-OH product availability as a result?
Why are we choosing prohibition over the KCPA regulatory framework that 15+ states have already implemented successfully?
This is a Winnable Fight
Rhode Island reversed its kratom ban in April 2026. Sound policy arguments, delivered to the right legislators at the right time, change outcomes.
Contact Your Legislators → Back to NMKA Home